# Zoetis Inc. (ZTS) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $82.99, market value $34.3 billion.

## Valuation
- **P/E (trailing): 13.6×** (5-yr avg 34.4×, 3-yr avg 29.0×). Zoetis Inc. trades at 13.6× trailing earnings, well below its own five-year average of 34.4×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.0×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.29**. A PEG of 1.29 is in the range usually read as fairly priced for its growth.
- **Price / sales: 3.6×**. Each dollar of revenue is priced at 3.6×.
- **Price / book: 10.9×**. The shares trade at 10.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 6.9%** (5-yr avg 2.6%). Free cash flow equals 6.9% of the market value, above its five-year average of 2.6%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 7.3%**. The inverse of the P/E: 7.3% of the price is earned each year.

## Profitability
- **Net margin: 28.2%**. 28.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 78.3%**. A 78.3% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on assets: 17.1%**. Each dollar of assets produces 17.1% of profit.

## Growth
- **Revenue growth (1 yr): 2.3%** (3-yr 5.4%/yr, 5-yr 7.2%/yr). Revenue grew 2.3% over the last year, against 7.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 10.1%** (3-yr 10.3%/yr, 5-yr 12.0%/yr). Earnings per share rose 10.1%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 19.9%/yr**. Free cash flow has compounded at 19.9% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 2.65**. Debt is 2.65 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Current ratio: 3.12** (quick 3.12). Current assets cover the next year's liabilities 3.12 times.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.55%** ($2.06 per share, trailing). Zoetis Inc. yields 2.55%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 33%**. 33% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 13**. 13 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 20.1%/yr** (1-yr 15.7%). The dividend has compounded at 20.1% a year over five years, doubling roughly every 4 years at that pace.

## Analyst view
- **Analyst consensus: hold** (13 analysts). 13 analysts cover Zoetis Inc.; the consensus is hold, with an average price target of $88.38 (+7% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -41.4%** (YTD -32.9%, 3-mo 7.9%). The shares are down 41.4% over twelve months including dividends.
- **From 52-week high: -37.4%** (20.7% above the low). Trading 37% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 68**. An RSI of 68 is neutral.
- **Beta (1 yr): 0.48** (volatility 39%). Beta of 0.48 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ZTS · Page: https://foliofundamentals.com/stocks/zts

Not investment advice.